

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Haohai Biological Technology Co., Ltd.*

上海昊海生物科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6826)

PROPOSED APPOINTMENT AND RE-ELECTION OF DIRECTORS AND SUPERVISORS

PROPOSED APPOINTMENT AND RE-ELECTION OF DIRECTORS

The term of office of the fourth session of the board (the “**Board**”) of directors (the “**Director(s)**”) of Shanghai Haohai Biological Technology Co., Ltd.* (the “**Company**”, together with its subsidiaries, the “**Group**”) will expire soon. A meeting of the Board was convened on 8 June 2022, at which, the Board proposed to (i) re-elect Dr. Hou Yongtai, Mr. Wu Jianying, Ms. Chen Yiyi, Mr. Tang Minjie, Ms. You Jie and Mr. Huang Ming as non-independent non-executive Directors (including executive Directors and non-executive Directors but excluding independent non-executive Directors) of the fifth session of the Board; and (ii) nominate Mr. Guo Yongqing and re-elect Mr. Jiang Zhihong, Mr. Su Zhi, Mr. Yang Yushe, Mr. Zhao Lei as the independent non-executive Directors of the fifth session of the Board. The above-mentioned are subject to the approval of the shareholders of the Company (the “**Shareholder(s)**”) by way of ordinary resolutions.

Ms. Li Yingqi will retire from her position as an independent non-executive Director and all positions in each of the special committees under the Board due to personal work arrangement, on the same date upon the election of a new independent non-executive Director by way of Shareholder’s approval. Ms. Li Yingqi has confirmed that she has no disagreement with the Board and there is no matter in respect of her retirement that needs to be brought to the attention of the Shareholders and The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”). The Company and the Board would like to express its gratitude to Ms. Li Yingqi for her diligence, fulfillment of due responsibility and contributions to the Company during her term of office.

The Directors of the fourth session of the Board will continue their tenure of office until the Directors of the fifth session of the Board are elected. In the event that the above-mentioned candidates for Directors are elected as Directors of the fifth session of the Board, their terms of office will be three years from the date of obtaining Shareholders’ approval. The Company will enter into service contracts with the Directors of the fifth session of the Board, the remuneration of whom will be determined in accordance with the remuneration plan of the Directors approved by the Shareholders and with reference to their respective duties and responsibilities in the Company and prevailing market conditions, and will be subject to review by the Board and the remuneration and appraisal committee of the Company from time to time.

RE-ELECTION OF SUPERVISORS

The term of office of the fourth session of the supervisory committee of the Company (the “**Supervisory Committee**”) will expire soon. A meeting of the Supervisory Committee was convened on 8 June 2022, at which, the Supervisory Committee proposed to re-elect Mr. Liu Yuanzhong, Ms. Yang Qing and Mr. Tang Yuejun as non-staff representative supervisors of the fifth session of the Supervisory Committee. The above-mentioned are subject to the approval of the Shareholders by way of ordinary resolutions.

The election of staff representative supervisors of the Company (the “**Supervisor(s)**”) shall be conducted by the staff of the Company democratically and is not subject to Shareholders’ approval. The Supervisors of the fourth session of the Supervisory Committee will continue their tenure of office until the Supervisors of the fifth session of the Supervisory Committee are elected.

In the event that the above-mentioned candidates for non-staff representative Supervisors are elected as Supervisors of the fifth session of the Supervisory Committee, their terms of office will be three years from the date of obtaining Shareholders’ approval. While the terms of office of staff representative Supervisors will become effective from the date of democratic election by the staff of the Company. The Company will enter into service contracts with the Supervisors of the fifth session of the Supervisory Committee, the remuneration of whom will be determined in accordance with the remuneration plan of the Supervisors approved by the general meeting, respectively.

BIOGRAPHICAL DETAILS OF THE NEW DIRECTOR CANDIDATE

Mr. Guo Yongqing (“**Mr. Guo**”), aged 48, has worked at Shanghai National Accounting Institute (上海國家會計學院) since 2002, and is currently a professor at Shanghai National Accounting Institute. Mr. Guo is a non-practicing member of the Chinese Institute of Certified Public Accountants (中國註冊會計師協會) and a member of Accounting Standards for Business Enterprises Consultative Committee of Ministry of Finance (財政部企業會計準則諮詢委員會). Mr. Guo served as an independent director at Chongqing Porton Pharmacy Science & Technology Co., Ltd. (重慶博騰製藥科技股份有限公司), a company listed on the Shenzhen Stock Exchange (stock code: 300363) during the period from March 2016 to May 2022. Mr. Guo has been serving as an independent non-executive director at Tianjin Capital Environmental Protection Group Company Limited (天津創業環保集團股份有限公司), a company listed on both Shanghai Stock Exchange (stock code: 600874) and the Hong Kong Stock Exchange (stock code: 1065) since December 2015. He has been serving as an independent director at Yango Group Co., Ltd. (陽光城集團股份有限公司), a company listed on the Shenzhen Stock Exchange (stock code: 000671) since May 2020. He has been serving as an independent director at Shanghai Electric Power Company Limited (上海電力股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 600021) since June 2021. Mr. Guo has also been serving as a director at Sanxiang Impression Co., Ltd. (三湘印象股份有限公司), a company listed on the Shenzhen Stock Exchange (stock code: 000863) since June 2021, and a director at Hwabao Securities Co. Ltd. (華寶證券股份有限公司) since September 2018. Mr. Guo obtained a doctoral degree in management majoring in accounting from Shanghai University of Finance and Economics (上海財經大學) in 2002.

Save as disclosed above, as at the date of this announcement, Mr. Guo (i) has not held any other positions with any members of the Group and has not had any other major appointments and professional qualifications; (ii) has not hold any directorships in public companies listed in Hong Kong or any other major exchanges in the last three years; (iii) does not have any relationship with any Directors, senior management or substantial Shareholders or controlling Shareholders of the Company; (iv) does not have any interest in any shares, underlying shares or debentures of the Company and its associated corporations which are required to be disclosed pursuant to Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, as at the date of this announcement, there are no other matters concerning the election of Mr. Guo that is required to be brought to the attention of the Shareholders and there are no other matters which shall be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Hong Kong Listing Rules**”).

Mr. Guo has confirmed his independence pursuant to Rule 3.13 of the Hong Kong Listing Rules. The Board also considers that Mr. Guo meets the independence guidelines set out in Rule 3.13 of the Hong Kong Listing Rules and is independent in accordance with the terms of the guidelines.

CIRCULAR

A circular containing details of the proposed appointment and re-election of Directors and Supervisors will be despatched to the Shareholders as soon as practicable in accordance with relevant requirements of the Hong Kong Listing Rules.

By order of the Board
Shanghai Haohai Biological Technology Co., Ltd.*
Hou Yongtai
Chairman

Shanghai, the PRC, 8 June 2022

As at the date of this announcement, the executive directors of the Company are Dr. Hou Yongtai, Mr. Wu Jianying, Ms. Chen Yiyi and Mr. Tang Minjie; the non-executive directors of the Company are Ms. You Jie and Mr. Huang Ming; and the independent non-executive directors of the Company are Ms. Li Yingqi, Mr. Jiang Zhihong, Mr. Su Zhi, Mr. Yang Yushe and Mr. Zhao Lei.

* For identification purpose only